Biosimilars and Follow-on Biologics 2016 Americas
02 Mar,2016 - 04 Mar,2016
A Little Teaser
The global biosimilars market is anticipated to reach $6.22 Billion by 2020 from $2.29 Billion in 2015, growing at a CAGR of 22.1% from 2015 to 2020. The increasing pressure to decrease healthcare expenditures, growing demand due to its cost-effectiveness, expanding occurrence of different diseases, increasing numbers of biologics losing their market exclusivity, positive outcomes in ongoing clinical trials and rising demand in various therapeutic applications are all contributing factors for growth of the biosimilars market.
Between 2015 and the end of 2019, 39 biologics with combined US sales of $41 billion, representing 30% of the total market will lose their marketing exclusivity. This resulted in huge interest by big pharma and biotech company venturing into the Biosimilar sector in order to gain a slice of multibillion worth of biologics market.
The FDA’s approval of the first Biosimilar product in the US is a significant event. A full blown Biosimilars market offers a huge potential in bettering patient outcomes and contributing compelling cost, opening the doors for easy access and optimal care. It was reported that Biosimilars could save the US economy up to $250 billion within the next seven years.
However, circumstance such as high manufacturing complexities and costs, rigorous regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict the entry of new players are restraining the growth of this market.
In this congress, we will cover a diverse range of topic and address the challenges and obstacles encountered by the industry from development to successful market of biosimilars. This will also offer and provide a unique platform for knowledge sharing and convergence from Pharmaceuticals, Biotechnology, Regulatory and many more.
I look forward to meeting you at the conference.
Jocelyn Raguindin Conference Director Paradigm Global Events